Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1213 ARTÍCULOS , VIENDO DEL 1141 AL 1155

Cerebrospinal fluid apolipoprotein E concentration and severity of cognitive impairment in patients with newly diagnosed Alzheimer's disease

Schmidt C, Becker H, Zerr I.

Am J Alzheimers Dis Other Demen. 2014 Feb;29(1):54-60. doi: 10.1177/1533317513505133. Epub 2013 Nov 24.

Chemical structure informing statistical hypothesis testing in metabolomics

Zhu H, Luo M.

Bioinformatics. 2014 Feb 15;30(4):514-22. doi: 10.1093/bioinformatics/btt708. Epub 2013 Dec 5.

Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study

Marksteiner J, Imarhiagbe D, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C.

Exp Gerontol. 2014 Feb;50:114-21. doi: 10.1016/j.exger.2013.12.001. Epub 2013 Dec 10.

A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative

Braskie MN, Thompson PM.

Biol Psychiatry. 2014 Apr 1;75(7):527-33. doi: 10.1016/j.biopsych.2013.11.020. Epub 2013 Nov 28.

CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility

Raj T, Ryan KJ, Replogle JM, Chibnik LB, Rosenkrantz L, Tang A, Rothamel K, Stranger BE, Bennett DA, Evans DA, De Jager PL, Bradshaw EM.

Hum Mol Genet. 2014 May 15;23(10):2729-36. doi: 10.1093/hmg/ddt666. Epub 2013 Dec 30.

Preventing cognitive decline in preclinical Alzheimer's disease

Riedel WJ.

Curr Opin Pharmacol. 2014 Feb;14:18-22. doi: 10.1016/j.coph.2013.10.002. Epub 2013 Nov 13.

The role of glial cells in Alzheimer disease: potential therapeutic implications

Lopategui Cabezas I, Herrera Batista A, Pentón Rol G.

Neurologia. 2014 Jun;29(5):305-9. doi: 10.1016/j.nrl.2012.10.006. Epub 2012 Dec 14.

The GGGGCC repeat expansion in C9ORF72 in a case with discordant clinical and FDG-PET findings: PET trumps syndrome

Adeli A, Savica R, Lowe VJ, Vemuri P, Knopman DS, Dejesus-Hernandez M, Rademakers R, Fields JA, Crum BA, Jack CR, Petersen RC, Boeve BF.

Neurocase. 2014;20(1):110-20. doi: 10.1080/13554794.2012.732090. Epub 2012 Nov 30.

Latino Alzheimer's disease caregivers and depression: using the stress coping model to examine the effects of spirituality and religion

Sun F, Hodge DR.

J Appl Gerontol. 2014 Apr;33(3):291-315. doi: 10.1177/0733464812444462. Epub 2012 May 15.

Amyloid and its association with default network integrity in Alzheimer's disease

Adriaanse SM, Sanz-Arigita EJ, Binnewijzend MA, Ossenkoppele R, Tolboom N, van Assema DM, Wink AM, Boellaard R, Yaqub M, Windhorst AD, van der Flier WM, Scheltens P, Lammertsma AA, Rombouts SA, Barkhof F, van Berckel BN.

Hum Brain Mapp. 2014 Mar;35(3):779-91. doi: 10.1002/hbm.22213. Epub 2012 Dec 14.

[Does Alzheimer's disease exist in all primates? Alzheimer pathology in non-human primates and its pathophysiological implications (II)]

Toledano A, Álvarez MI, López-Rodríguez AB, Toledano-Díaz A, Fernández-Verdecia CI.

Neurologia. 2014 Jan-Feb;29(1):42-55. doi: 10.1016/j.nrl.2011.05.004. Epub 2011 Aug 25.

Changes in gait variability with anti-dementia drugs: a systematic review and meta-analysis

Beauchet O, Launay CP, Allali G, Annweiler C.

CNS Drugs. 2014 Jun;28(6):513-8. doi: 10.1007/s40263-014-0170-6.

Alzheimer disease and type 2 diabetes mellitus: the link to tyrosine hydroxylase and probable nutritional strategies

Aliev G, Shahida K, Gan SH, Firoz C, Khan A, Abuzenadah AM, Kamal W, Kamal MA, Tan Y, Qu X, Reale M.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):467-77. doi: 10.2174/18715273113126660153.

Neuropathology of parkinsonism in patients with pure Alzheimer's disease

Horvath J, Burkhard PR, Herrmann FR, Bouras C, Kövari E.

J Alzheimers Dis. 2014;39(1):115-20. doi: 10.3233/JAD-131289.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias